AstraZeneca PLC (NASDAQ:AZN) ranks among the best-performing European stocks to invest in. Following the release of Phase 3 trial data for baxdrostat at ESC 2025, Goldman Sachs reaffirmed its Conviction Buy rating on AstraZeneca PLC (NASDAQ:AZN) on September 1. The Phase 3 BaxHTN trial found that baxdrostat reduced seated systolic blood pressure (SBP) in a dose-dependent, placebo-adjusted manner at week 12. Pixabay/Public Domain According to safety data, both the 2 mg and 1 mg doses had confirmed rates ...